Opiant Pharmaceuticals announces CFIUS approval for acquisition by Indivior

Opiant Pharmaceuticals announced that the Committee on Foreign Investment in the United States, or CFIUS, approved the previously announced merger agreement for Opiant to be acquired by Indivior. Following the expiration of the waiting period under the U.S. Hart-Scott-Rodino Act of 1976, as amended, which Opiant previously announced, on February 6, the parties received written notice from CFIUS that it had determined that there were no unresolved national security concerns regarding the transaction and that it had concluded action under Section 721 of the Defense Production Act of 1950, as amended, thereby clearing the transaction contemplated by the Agreement. Additionally, the Competition and Markets Authority in the United Kingdom has elected to take no action with regard to the proposed merger. The proposed merger remains subject to approval by Opiant stockholders. A special meeting of Opiant’s stockholders to approve the agreement will be held on March 1. Indivior and Opiant continue to anticipate completing the Agreement in the first quarter.